Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes
Latest Information Update: 07 Nov 2021
At a glance
- Drugs NY ESO 1 TCR Kite Pharma (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Mesna
- Indications Malignant melanoma; Meningioma; Solid tumours
- Focus Therapeutic Use
- 07 Apr 2020 Status changed from recruiting to completed.
- 17 Apr 2019 Planned End Date changed from 28 Jul 2018 to 28 Jul 2028.
- 23 Jun 2017 Planned primary completion date changed from 3 Jul 2017 to 5 Jul 2027.